|
Sign In to gain access to subscriptions and/or personal tools.
|
Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia
Lei Wang
Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Lan Yu
Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Ai-Ping Zhang
Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Chao Fang
Bio-X Center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Jing Du
Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Niu-Fan Gu
Shanghai Institute of Mental health, Shanghai, China
Sheng-Ying Qin
Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Guo-Yin Feng
Shanghai Institute of Mental health, Shanghai, China
Xing-Wang Li
Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China
Qing-He Xing
Bio-X center, Shanghai Jiao Tong University, Shanghai, China, Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China, xinqinghe{at}sjtu.edu.cn
Lin He
Institute for Nutritional Science, Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, Shanghai, China, NHGG, Bio-X center, Shanghai Jiao Tong University, Shanghai, China, helin{at}bio-x.cn
The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. One-hundred and eighteen Chinese schizophrenia patients (40 males, 78 females, age 15—60 years) were given risperidone at dosages ranging from 2—8 mg/day for 8 weeks. Clinical efficacy was determined using the Brief Psychiatric Rating Scores (BPRS). Serum prolactin levels were assayed before and after the 8 week treatment and plasma risperidone and 9-hydroxyrisperidone levels were also measured at the end of the 8-week treatment. The results showed there was no significant correlation between the concentration of active moiety and clinical response. Risperidone treatment significantly increased serum prolactin levels. Furthermore, changes of prolactin levels were not correlated with the clinical response. For the risperidone/ 9-hydroxyrisperidone ratio, there was a statistically significant difference among the CYP2D6*1/*1, *1/*10, *10/*10 genotypes (Kruskal—Wallis test, p = 0.012). No significant differences were found in the concentration of 9-hydroxyrisperidone and active moiety among the genotypes. In addition, the concentration of 9-hydroxyrisperidone was not significantly correlated with the increase of serum prolactin. In conclusion, our study has, for the first time, produced evidence that in Chinese schizophrenic patients, the metabolism of risperidone is dependent on CYP2D6. Neither changes in serum prolactin levels nor plasma concentration of active moiety were significantly correlated with clinical efficacy of risperidone. 9-hydroxyrisperidone may not play a predominant role in elevating serum prolactin level.
Key Words: schizophrenia CYP2D6 clinical response prolactin risperidone 9-hydroxyrisperidone
References
- Bondolfi G., Dufour H., Patris M., May J.P., Billeter U., Eap C.B., Baumann P. (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155: 499—504[Abstract/Free Full Text]
- Chou J.C., Douyon R., Czobor P., Volavka J., Cooper T.B. (1998) Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Psychiatry Res 81: 51—55[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Chouinard G., Arnott W. Clinical review of risperidone (1993) Can J Psychiatry 38(Suppl 3): S89—S95[Web of Science][Medline]
[Order article via Infotrieve]
- David S.R., Taylor C.C., Kinon B.J., Breier A. (2000) The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 22: 1085—1096[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Douglas A.M., Atchison B.A., Somogyi A.A., Drummer O.H. (1994) Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/sparteine genetic polymorphism. Pharmacogenetics 4: 154—158[Web of Science][Medline]
[Order article via Infotrieve]
- Fang J., Bourin M., Baker G.B. (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359: 147—151[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Heim M., Meyer U.A. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529—532[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Hersberger M., Marti-Jaun J., Rentsch K., Hanseler E. (2000) Rapid detection of the CYP2D6*3, CYP2D6*4 and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. Clin Chem 46: 1072—1077[Abstract/Free Full Text]
- Huang M.L., Van Peer A., Woestenborghs R., De Coster R., Heykants J., Jansen A.A., Zylicz Z., Visscher H.W., Jonkman J.H. (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257—268[Web of Science][Medline]
[Order article via Infotrieve]
- Kapur S., Roy P., Daskalakis J., Remington G., Zipursky R. (2001) Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am J Psychiatry 158: 311—314[Abstract/Free Full Text]
- Knegtering R., Baselmans P., Castelein S., Bosker F., Bruggeman R., Van den Bosch R.J. (2005) Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162: 1010—1012[Abstract/Free Full Text]
- Lee B.H., Kim Y.K. (2006) The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Prog Neuropsychopharmacol Biol Psychiatry 30: 658—662[CrossRef][Medline]
[Order article via Infotrieve]
- Lee H.S., Tan C.H., Khoo Y.M., Chee K.T., Wong K.E., Chong S.A., Mahendran R., Yap J.L., Low B.L., Choo C.H., Chan A. ( 1999) Serum concentrations and clinical effects of risperidone in schizophrenic patients in Singapore—a preliminary report. Br J Clin Pharmacol 47: 460—461[Web of Science][Medline]
[Order article via Infotrieve]
- Leysen J.E., Gommeren W., Eens A., De Chaffoy D.C., Stoof J.C., Janssen P.A. (1998) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661—670
- Markianos M., Hatzimanolis J., Lykouras L. (1999) Gonadal axis hormones in male schizophrenic patients during treatment with haloperidol and after switch to risperidone. Psychopharmacology (Berl) 143: 270—272[CrossRef][Medline]
[Order article via Infotrieve]
- Matsubara Y., Ohnuma T., Shibata N., Takahashi T., Arai H. ( 2002) Plasma concentration of risperidone showed a correlation with daily dose, but not with age nor cytochrome P-450 2D6 gene polymorphisms in Japanese schizophrenics. Psychogeriatrics 2: 284—288[CrossRef]
- Mauri M.C., Laini V., Boscati L., Rudelli R., Salvi V., Orlandi R., Papa P. ( 2001) Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry 16: 57—63[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Meltzer H.Y., Busch D.A., Fang V.S. (1983) Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 9: 271—283[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Mihara K., KondoT., Yasui-Furukori N., Suzuki A., Ishida M., Ono S., Kubota T., Iga T., Takarada Y., De Vries R., Kaneko S. (2003) Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25: 287—293[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Olesen O.V., Linnet K. (1997) Simplified high-performance liquid chromatographic method of determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B 698: 209—216[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Olesen O.V., Licht R.W., Thomsen E., Bruun T., Viftrup J.E., Linnet K. (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20: 380—384[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Overall J.E., Gorham D.R. (1962) The brief psychiatric rating scale. Psychol Rep 10: 799—812[Web of Science]
- Roh H.K., Dahl M.L., Johansson I., Ingelman-Sundberg M., Cha Y.N., Bertilsson L. (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6: 441—447[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Roh H.K., Kim C.E., Chung W.G., Park C.S., Svensson J.O., Bertilsson L. (2001) Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol 57: 671—675[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Shingo K., Reiji Y., Koji S., Chima M., Makiko G., Kyoko K., Yasuhisa Y., Nobuhisa U., Osamu O., Jun N. ( 2005) Prediction of response to risperidone treatment with respect to plasma concentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20: 71—78[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Scordo M.G., Spina E., Facciola G., Avenoso A., Johansson I., Dahl M.L. (1999) Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl) 147: 300—305[CrossRef][Medline]
[Order article via Infotrieve]
- Spina E., Avenoso A., Facciola G., Salemi M., Scordo M.G., Ancione M., Madia A.G., Perucca E. (2001) Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 153: 238—243[CrossRef][Medline]
[Order article via Infotrieve]
- van Beijsterveldt L.E., Geerts R.J., Leysen J.E., Megens A.A., Van den Eynde H.M., Meuldermans W.E., Heykants J.J. (1994) Regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology (Berl) 114: 53—62[CrossRef][Medline]
[Order article via Infotrieve]
- Van Putten T, Marder S.R., Mintz J. (1991) Serum prolactin as a correlate of clinical response to haloperidol. J Clin Psychopharmacol 11: 357—361[Web of Science][Medline]
[Order article via Infotrieve]
- Xie H.G., Kim R.B., Wood A.J., Stein C.M. (2001) Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 41: 815—850[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
- Yasui-Furukori N., Mihara K., Kondo T., Kubota T., Iga T., Takarada Y., De Vries R., Kaneko S., Tateishi T. (2003) Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 43: 122—127[Abstract/Free Full Text]
- Zhang X.Y., Zhou D.F., Yuan C.L., Zhang P.Y., Wu G.Y., Shen Y.C. (2002) Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Psychiatry Res 109: 297—302[CrossRef][Web of Science][Medline]
[Order article via Infotrieve]
This version was published on November
1, 2007
Journal of Psychopharmacology, Vol. 21, No. 8,
837-842 (2007)
DOI: 10.1177/0269881107077357

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
|
|